Cargando…

Gene expression in human sepsis: what have we learned?

In the previous issue of Critical Care, Tang and colleagues offer a very novel systematic review of 12 studies of gene expression in blood of human sepsis. The review concludes that there is no discernable transition from a pro- to an anti-inflammatory expression phenotype in blood in human sepsis....

Descripción completa

Detalles Bibliográficos
Autor principal:	Russell, James A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222025/ https://www.ncbi.nlm.nih.gov/pubmed/21392407 http://dx.doi.org/10.1186/cc9384

Ejemplares similares

Recent progress in sepsis epidemiology – have we learned enough?
por: Gerlach, Herwig, et al.
Publicado: (2003)

Commentary: Thoracoscopic-Assisted Rib Plating: Where We Are and What We Have Learned
por: Kim, Seon Hee, et al.
Publicado: (2023)

Commentary: What do we still have to learn from surgery?
por: Belluschi, Igor, et al.
Publicado: (2021)

What have we learned from cancer immunotherapy in the last 3 years?
por: Ascierto, Paolo A, et al.
Publicado: (2014)

Brain dysfunction in sepsis: what can we learn from cerebral perfusion studies?
por: Steiner, Luzius A
Publicado: (2008)

History of gestational diabetes and future cardiovascular disease: What have we learned?
por: Hsu, Cherng‐Lan, et al.
Publicado: (2018)

Coronavirus Disease 2019 and Acute Kidney Injury: What Have We Learned?
por: Husain-Syed, Faeq, et al.
Publicado: (2021)

COVID-19 and patient engagement in health research: What have we learned?
por: Denegri, Simon, et al.
Publicado: (2021)

Commentary: Patient Perspectives on Artificial Intelligence; What have We Learned and How Should We Move Forward?
por: Camaradou, Jennifer Catherine Louise, et al.
Publicado: (2023)

Targeting cytokine storm in COVID-19: what have we learned?
por: Ridker, Paul M
Publicado: (2021)

Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
por: Tang, Jordan, et al.
Publicado: (2011)

Qualitative research on community experiences in large HIV research trials: what have we learned?
por: Camlin, Carol S, et al.
Publicado: (2018)

Estimating maternal mortality: what have we learned from 16 years of surveys in Afghanistan?
por: Alba, Sandra, et al.
Publicado: (2020)

Violence against children in the time of COVID-19: What we have learned, what remains unknown and the opportunities that lie ahead
por: Fore, Henrietta H.
Publicado: (2021)

Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?
por: Ewer, Michael S., et al.
Publicado: (2016)

Clinical trial registration during COVID-19 and beyond in the African context: what have we learned?
por: Mathebula, Lindi, et al.
Publicado: (2022)

Metasynthetic Madness: What Kind of Monster Have We Created?
por: Thorne, Sally
Publicado: (2016)

Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2005)

Time-restricted feeding: what we have done and what more we can do?
por: Sun, Yuning, et al.
Publicado: (2023)

Surrogate end points of quality of life assessment: have we really found what we are looking for?
por: Tassinari, Davide
Publicado: (2003)

Look Action for Health in Diabetes trial: What we have learned in terms of real world practice and clinical trials
por: Kwok, Ching-Fai, et al.
Publicado: (2014)

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Covid-19 and drug therapy, what we learned
por: Provenzani, Alessio, et al.
Publicado: (2020)

Acute stroke: we have the treatments and we have the evidence – we need to use them
por: Quinn, Terence J, et al.
Publicado: (2007)

Parliaments lead the change for women’s, children’s and adolescents’ health: what have we learnt?
por: Toure, Kadidiatou, et al.
Publicado: (2021)

Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?
por: Kamath, Shiwani, et al.
Publicado: (2023)

Neutrinos, what we have learned about them and what we have learned using them
por: Steinberger, J
Publicado: (2013)

Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here?
por: Griesdale, Donald EG
Publicado: (2012)

The impact of public involvement in health research: what are we measuring? Why are we measuring it? Should we stop measuring it?
por: Russell, Jill, et al.
Publicado: (2020)

Proximal tubular dysfunction in patients with COVID-19: what have we learnt so far?
por: Braun, Fabian, et al.
Publicado: (2020)

Cannabis use in first episode psychosis: what we have tried and why it hasn’t worked
por: McDonell, Michael G., et al.
Publicado: (2019)

What can we learn from the islet of Joslin Medalists?
por: Yagihashi, Soroku
Publicado: (2020)

What will we choose to learn from the COVID-19 pandemic?
por: Bayingana, Alice Uwase, et al.
Publicado: (2021)

GOAL: What Have We Learned?
por: Leek, Timothy K Vander
Publicado: (2005)

SARS: What have we learned?
Publicado: (2003)

What have we learned on mesons?
por: Moebes, J P
Publicado: (1972)

Food safety in Vietnam: where we are at and what we can learn from international experiences
por: Nguyen-Viet, Hung, et al.
Publicado: (2017)

Micronutrients in Sepsis and COVID-19: A Narrative Review on What We Have Learned and What We Want to Know in Future Trials
por: Rossetti, Matteo, et al.
Publicado: (2021)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7hcfasrrob0c3t7itjvmsfcbfa